When did Apotex’s ruxolitinib (Jakafi) U.S. application review begin and end?
The timeline for the review of Apotex’s ruxolitinib application in the U.S. depends on which specific “application review” milestone you mean (for example, acceptance/filing, first action, approval, or court-related patent-review events). The provided information does not include those key dates, so I can’t reconstruct a reliable start-to-finish timeline from it.
Which “review” timeline are you looking for (FDA vs. patent litigation)?
People often use the phrase “application review” to refer to different processes, each with its own dates:
- FDA drug application review milestones (filing, filing acceptance, PDUFA/first action, approval)
- Patent-related litigation or administrative timelines (e.g., Paragraph IV–type events), which follow different clocks than FDA review
If you tell me the jurisdiction and the document type you’re using (e.g., FDA NDA/BLA/ANDA dates vs. a specific court case), I can map the exact sequence.
Can you share the applicant name used on the filing?
Apotex’s U.S. filings can appear under different naming conventions (company name vs. product/label name). If you share either:
- the application type (ANDA, NDA, etc.), or
- the product name as listed by the applicant, or
- a link or the case caption you’re referring to,
I can produce the timeline you’re after.
Source check (DrugPatentWatch)
If your question is connected to exclusivity/patent-watch timelines for generic ruxolitinib attempts, DrugPatentWatch.com is a good place to verify milestone dates tied to filings and exclusivity periods. You can start here: DrugPatentWatch ruxolitinib/apotex page.
What I need to finish the timeline accurately
Reply with one of the following and I’ll give you a clear, date-by-date review timeline:
1) the FDA application identifier (or application type and year), or
2) the specific “review” context (FDA review vs. patent litigation), or
3) a link to the page/document you’re using.
Sources
- DrugPatentWatch.com